New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 2, 2014
12:49 EDTAGENAgenus price target lowered to $6 from $11 at Maxim
Maxim views the data that Agenus announced for its Heat Shock Protein Vaccine as positive however, but also thinks the company is now likely to seek a partnership to support a pivotal trial. The firm, which previously thought Agenus might be in a position to file for approval with phase II data, lowered its price target on the stock to $6 but keeps its Buy rating on the name.
News For AGEN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 26, 2015
07:08 EDTAGENAgenus reports Q4 EPS (41c), consensus (16c)
Reports Q4 revenue $1.62M, consensus $620K. Target Milestones for 2015 include: Publication of the Phase 2 data for Prophage in newly diagnosed GBM in a peer reviewed journal. Explore options for the advancement of Prophage for newly diagnosed GBM to a Phase 3 trial. Full Phase 3 data for partner GlaxoSmithKline’s HZ/su shingles vaccine are expected to be presented at a scientific conference and submitted for publication in a peer-reviewed journal. The vaccine contains Agenus’ proprietary QS-21 Stimulon adjuvant. EMA regulatory decision on GlaxoSmithKline’s malaria vaccine candidate RTS,S, which contains Agenus’s QS-21 Stimulon adjuvant. File Investigational New Drug applications for two checkpoint modulator antibody programs as part of our global oncology alliance with Incyte.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use